

# EGFR TKI: SINGLE AGENT OR IN COMBINATION?

**ROOM B  
PALEXPO**  
GENEVA, SWITZERLAND

## Chairs

David Planchard, France  
Edward Garon, USA

This educational activity is provided by ESMO  
and supported by Lilly.



**THURSDAY, 16 APRIL 2020**  
09:15 – 10:45

- 
- 09:15 EGFR TKI in first-line: First/second generation TKI or osimertinib upfront?  
*David Planchard, Villejuif, France*
- 
- 09:30 Should EGFR TKI be used in combination with chemotherapy?  
*Enriqueta Felip, Barcelona, Spain*
- 
- 09:45 What is the contribution of anti-angiogenic added to EGFR TKI?  
*Martin Reck, Grosshansdorf, Germany*
- 
- 10:00 Do immune check-point inhibitors work in EGFR mutant?  
*Edward Garon, Santa Monica, CA, USA*
- 
- 10:15 One case of EGFR mutant  
*Elisa Onesti, Liège, Belgium*
- 
- 10:30 Expert panel discussion: Questions from the audience  
*All*

